Information For Healthcare Professionals
Patients are still developing severe mpox. A March 3, 2023, MMWR provides updated clinical treatment considerations about using therapeutics to treat severe mpox cases, including ocular infections, neurologic complications, myopericarditis, complications associated with mucosal lesions, and complications from uncontrolled viral spread.
CDC has updated its Interim Clinical Considerations for using the JYNNEOS and ACAM2000 vaccines during the 2022 U.S. mpox outbreak, including an alternative regimen for administering the JYNNEOS vaccine intradermally.
CDC urges healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox.
When properly administered before an exposure, vaccines are effective at protecting people against mpox.